Abbott Laboratories (NYSE:ABT) Shares Bought by OneAscent Financial Services LLC

OneAscent Financial Services LLC raised its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 49.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,824 shares of the healthcare product maker's stock after purchasing an additional 2,267 shares during the period. OneAscent Financial Services LLC's holdings in Abbott Laboratories were worth $772,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Welch Group LLC raised its stake in Abbott Laboratories by 5.3% during the fourth quarter. Welch Group LLC now owns 68,653 shares of the healthcare product maker's stock valued at $7,744,000 after purchasing an additional 3,479 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its position in shares of Abbott Laboratories by 5.5% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,095,443 shares of the healthcare product maker's stock valued at $133,691,000 after buying an additional 57,499 shares in the last quarter. Bath Savings Trust Co lifted its holdings in shares of Abbott Laboratories by 3.7% in the 4th quarter. Bath Savings Trust Co now owns 166,132 shares of the healthcare product maker's stock valued at $18,791,000 after acquiring an additional 5,881 shares during the last quarter. Bank Pictet & Cie Europe AG grew its position in Abbott Laboratories by 1.9% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after acquiring an additional 2,774 shares in the last quarter. Finally, Pensionfund Sabic bought a new stake in Abbott Laboratories during the fourth quarter worth approximately $2,828,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Remove Ads

Abbott Laboratories Stock Up 1.1 %

Shares of ABT stock traded up $1.31 during mid-day trading on Tuesday, hitting $126.17. The stock had a trading volume of 2,872,504 shares, compared to its average volume of 5,911,053. The firm has a market capitalization of $218.82 billion, a P/E ratio of 16.51, a price-to-earnings-growth ratio of 2.52 and a beta of 0.80. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23. The firm's 50-day moving average is $131.08 and its two-hundred day moving average is $120.95.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.97 billion for the quarter, compared to analysts' expectations of $11.03 billion. During the same period in the prior year, the business earned $1.19 EPS. The firm's quarterly revenue was up 7.2% on a year-over-year basis. On average, analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 annualized dividend and a yield of 1.87%. Abbott Laboratories's dividend payout ratio (DPR) is presently 30.85%.

Insider Activity

In other Abbott Laboratories news, EVP Lisa D. Earnhardt sold 91,167 shares of the business's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the sale, the executive vice president now owns 71,928 shares in the company, valued at approximately $9,625,404.96. The trade was a 55.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the transaction, the executive vice president now directly owns 125,697 shares of the company's stock, valued at $16,152,064.50. This represents a 15.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 116,449 shares of company stock worth $15,463,316. 0.46% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. The Goldman Sachs Group lifted their target price on Abbott Laboratories from $138.00 to $154.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. UBS Group lifted their price objective on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. Citigroup increased their target price on shares of Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Bank of America lifted their price target on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Finally, StockNews.com lowered shares of Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $137.94.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.